Cyclopharm Limited Stock

Equities

CYC

AU000000CYC5

Advanced Medical Equipment & Technology

Delayed Australian S.E. 08:02:15 2024-04-18 pm EDT 5-day change 1st Jan Change
1.78 AUD 0.00% Intraday chart for Cyclopharm Limited -0.28% -7.53%
Sales 2024 * 37.4M 23.83M Sales 2025 * 60.9M 38.8M Capitalization 168M 107M
Net income 2024 * -2M -1.27M Net income 2025 * 11M 7.01M EV / Sales 2024 * 4.48 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.75 x
P/E ratio 2024 *
-70 x
P/E ratio 2025 *
14.3 x
Employees 87
Yield 2024 *
0.57%
Yield 2025 *
3.49%
Free-Float 45.15%
More Fundamentals * Assessed data
Dynamic Chart
1 week-0.28%
Current month-0.84%
3 months-5.57%
6 months-21.93%
Current year-7.53%
More quotes
1 week
1.78
Extreme 1.78
1.80
1 month
1.77
Extreme 1.77
1.84
Current year
1.72
Extreme 1.715
1.97
1 year
1.72
Extreme 1.715
3.15
3 years
0.95
Extreme 0.95
3.15
5 years
0.70
Extreme 0.7
3.45
10 years
0.20
Extreme 0.2
3.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-06-02
Chief Operating Officer - 16-12-31
Corporate Officer/Principal - 19-09-29
Members of the board TitleAgeSince
Director/Board Member 63 21-08-09
Chief Executive Officer 58 08-06-02
Chairman 79 06-11-19
More insiders
Date Price Change Volume
24-04-18 1.78 0.00% 5 000
24-04-18 1.78 -1.11% 15,980
24-04-17 1.8 +0.84% 2,000
24-04-16 1.785 0.00% 3,780
24-04-15 1.785 0.00% 502

Delayed Quote Australian S.E., April 18, 2024 at 08:02 pm EDT

More quotes
Cyclopharm Limited is an Australia-based health technology company. The Company’s principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. Its subsidiaries include Cyclomedica Europe Limited, Cyclomedica Australia Pty Limited and Cyclomedica Canada Limited.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.146 USD
Average target price
3.004 USD
Spread / Average Target
+162.07%
Consensus

Quarterly revenue - Rate of surprise